Atlantic American Files Long-Delayed FY2025 10-K: $6.0M Net Income, Three Material Weaknesses, Nasdaq Delisting Risk
AAME is trading near its 52-week low of $1.032 (1.8% above the low) on light trading volume (0.1× avg).
Summary
Atlantic American filed its overdue FY2025 10-K showing $6.0 million of net income (mostly non-cash investment gains), but disclosed three material weaknesses in internal controls, a restatement of 2024 results, and an expected Nasdaq delisting determination after missing its compliance deadline.
Key Events · Earnings and Guidance · AAME
-
FY2025 Net Income of $6.0 Million
Net income of $6.0 million, or $0.28 per diluted share, versus a restated net loss of $1.4 million, or $(0.09) per share, in 2024. Total revenue rose to $210.4 million from $188.1 million restated.
-
Profit Driven by Non-Cash Investment Gains
The swing to profit was largely non-operating: $4.5 million of unrealized gains on equity securities and a $4.9 million future policy benefit remeasurement gain, versus a $0.5 million realized investment loss. Non-GAAP operating income was only $3.7 million.
-
Three Material Weaknesses Disclosed
Management concluded internal control over financial reporting was not effective as of December 31, 2025 due to material weaknesses in group premium receivables/suspense cash application, LDTI implementation and valuation, and income tax accounting. Remediation is underway but unremediated.
-
2024 Financials Revised for Premium Receivable Errors
The company revised previously issued 2024 statements, reducing insurance premiums and other receivables by $5.580 million, retained earnings by $1.485 million, and increasing 2024 net loss by $0.277 million. Management deemed the errors immaterial to prior periods but material if corrected entirely in 2025.
Analysis · AAME · Finance
After missing the deadline by roughly seven months, Atlantic American has finally filed its FY2025 annual report, and the filing reveals a company under real stress. On the surface, the headline numbers look fine: $6.0 million of net income ($0.28 per diluted share) versus a $1.4 million restated loss in 2024, on revenue of $210.4 million. But the quality of that result is questionable, driven by a $4.5 million non-cash unrealized gain on equity securities and a $4.9 million future policy benefit remeasurement gain, not by core underwriting. More importantly, management disclosed three separate material weaknesses in internal control over financial reporting (group premium receivables and suspense cash application, LDTI implementation, and income tax accounting), revised its previously issued 2024 financial statements to remove $5.6 million of invalid premium receivables, and said it expects a Nasdaq staff delisting determination because it could not file its delinquent quarterly reports by the October 12, 2026 extension deadline. The company also disclosed that its CFO resigned in May 2026 and that its principal insurance subsidiary has not filed required statutory financial statements with state regulators. For a $21 million market cap insurer trading near its 52-week low, the combination of a delisting threat, unremediated material weaknesses, a restatement and a CFO vacancy is a serious governance and survival story that outweighs the modest reported profit.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 43.7% of the 286 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AAME was trading at $1.05 on NASDAQ in the Finance sector, with a market capitalization of approximately $21.4M. The 52-week trading range was $1.03 to $3.24. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.